Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report

BACKGROUND: Aumolertinib (HS-10296), a 3rd-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been shown to have efficacy in treating tumors harboring EGFR sensitive mutations: EGFR in-frame deletions or insertions within exon 19 deletion (19Del) and the exon 21...

Descripció completa

Dades bibliogràfiques
Autors principals: Qin, Zhiquan, Zhang, Hang, Yan, Peiyuan, Yu, Lili, Hong, Chaojin, Calvetti, Lorenzo, Passaro, Antonio, Araujo, Antonio, Chen, Yun
Format: Online Article Text
Idioma:English
Publicat: AME Publishing Company 2023
Matèries:
iMDT Corner
Accés en línia:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407486/
https://www.ncbi.nlm.nih.gov/pubmed/37559636
http://dx.doi.org/10.21037/jtd-23-841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407486/
https://www.ncbi.nlm.nih.gov/pubmed/37559636
http://dx.doi.org/10.21037/jtd-23-841

Ítems similars